Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics
| ISSN | 09594973, 14735741 |
|---|---|
| Country | United States |
| Publisher | Lippincott Williams & Wilkins Ltd. |
| Subject Areas | Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics |
| Publication Type | Journals |
| Active Years | 1990-ongoing |
| Competitiveness | 1. (0-20) Least Competitive |
| Publication Time | 2. Quick (1-3 months) |
| Website | Visit journal |
| JIF 2022–2023 | 1.800 |
| 2019-2020 SCR Rank | 5008 |
| 2020-2021 SCR Rank | 6972 |
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy.
| Year | 2-Year IF | 3-Year IF | 4-Year IF |
|---|---|---|---|
| 2023 | 1.887 | 1.987 | 1.967 |
| 2022 | 2.233 | 2.256 | 2.282 |
| 2021 | 2.270 | 2.381 | 2.510 |
| 2020 | 2.101 | 2.289 | 2.131 |
| 2019 | 2.362 | 2.142 | 2.056 |
| 2018 | 1.870 | 2.015 | 2.074 |
| 2017 | 1.773 | 2.033 | 2.077 |
| 2016 | 2.513 | 2.436 | 2.291 |
| 2015 | 2.398 | 2.271 | 2.229 |
| 2014 | 2.065 | — | — |
| 2013 | 2.250 | — | — |
| 2012 | 2.795 | — | — |
| 2011 | 2.663 | — | — |
| 2010 | 2.504 | — | — |
| 2009 | 2.623 | — | — |
| 2008 | 2.635 | — | — |
| 2007 | 2.679 | — | — |
| 2006 | 2.791 | — | — |
| 2005 | 2.122 | — | — |
| 2004 | 2.311 | — | — |
| 2003 | 2.185 | — | — |
| 2002 | 2.214 | — | — |
| 2001 | 1.649 | — | — |
| 2000 | 1.578 | — | — |
Note: impact factor data for reference only.
SJR measures scientific influence, weighting citations by the prestige of the citing journal.
| Year | SJR Score |
|---|---|
| 2023 | 0.476 |
| 2022 | 0.471 |
| 2021 | 0.463 |
| 2020 | 0.651 |
| 2019 | 0.636 |
| 2018 | 0.684 |
| 2017 | 0.716 |
| 2016 | 0.780 |
| 2015 | 0.783 |
The H-Index measures both the productivity and citation impact of a journal's publications.
| Year | H-Index |
|---|---|
| 2023 | 102.000 |
| 2022 | 98.000 |
| 2021 | 96.000 |
| 2020 | 93.000 |
https://journals.lww.com/anti-cancerdrugs/_layouts/15/1033/oaks.journals/informationforauthors.aspx